Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Bevacizumab in Recurrent Grade II and III Glioma (TAVAREC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01164189
Recruitment Status : Completed
First Posted : July 16, 2010
Last Update Posted : February 28, 2019
Hoffmann-La Roche
Information provided by (Responsible Party):
European Organisation for Research and Treatment of Cancer - EORTC

No Study Results Posted on for this Study
Recruitment Status : Completed
Actual Primary Completion Date : January 19, 2017
Actual Study Completion Date : September 24, 2017